Trial Profile

A proof of concept trial of AAV-based gene therapies

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AAV based gene therapies Asklepios BioPharmaceutical/Selecta Biosciences (Primary)
Indications Glycogen storage disease type II
Focus Adverse reactions; Proof of concept

Most Recent Events

01 Sep 2020 According to a Selecta Biosciences media release, the company will receive an additional $10 million through September 30, 2021 upon enrollment of first patient in this trial.
12 May 2020 New trial record
07 May 2020 According to a Selecta Biosciences media release, Selecta and AskBio anticipate initiating the study by the end of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com